Cloverleaf Bio, a spinout out of Yale, announced $33M in seed financing today that will help it advance its work on a tRNA platform in oncology
- 5 hours ago
- 1 min read
Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the co-lead programs target hepatocellular carcinoma and colorectal cancer) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.










.png)